MedTrace Logo

Evaluating the Feasibility of Disseminating a Novel Mobile Platform to Treat Depression

NCT02817672 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-01-22

No results posted yet for this study

Summary

The goal of this project is to conduct a pilot study to test the utility of a Natural Language Processing (NLP) clinical messaging tool to improve the reach and the quality (fidelity and competency) of coaches providing behavioral activation (BA) strategies through a mobile mental health app called Personalized Real-time Intervention for Motivational Enhancement (PRIME). This study will improve the reach of clinicians by using a NLP-powered messaging tool, which will ensure fidelity to the BA model and clinicians will have access to real-time clinical information about their patients to guide more targeted treatment (competence). If successful, PRIME could operate as a cost effective tool for clinicians to extend their reach and an accessible treatment for the population of those struggling with depression.

Conditions

Interventions

BEHAVIORAL

PRIME 1.0

Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).

BEHAVIORAL

PRIME 2.0

Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).

Sponsors & Collaborators

Principal Investigators

  • Danielle Schlosser, PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-25
Primary Completion
2018-04-10
Completion
2018-04-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02817672 on ClinicalTrials.gov